Deserpidine is a naturally occurring indole alkaloid extracted from the roots of the Rauwolfia serpentina plant. It has been used in traditional Indian medicine for centuries to treat various ailments, including high blood pressure. It is a potent inhibitor of the enzyme monoamine oxidase (MAO), which is involved in the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine. Deserpidine's effects are primarily attributed to its ability to deplete the body's stores of these neurotransmitters. This depletion leads to a reduction in sympathetic nervous system activity, resulting in a decrease in blood pressure. Deserpidine has been used in the treatment of hypertension, but it has been largely replaced by other drugs with fewer side effects. Research into deserpidine continues, focusing on its potential as an anti-cancer agent and its role in the development of new drugs for neurodegenerative diseases like Alzheimer's disease.'
deserpidine: minor descriptor (66-84); on-line search RESERPINE/AA (75-84), RESERPINE (66-74); Index Medicus search RESERPINE/AA (75-84), YOHIMBANS (69-74), RESERPINE (66-68); RN given refers to (3beta,16beta,17alpha,18beta,20alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8550 |
| CHEMBL ID | 1200515 |
| CHEBI ID | 27478 |
| SCHEMBL ID | 259343 |
| MeSH ID | M0262623 |
| Synonym |
|---|
| methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate |
| a-11025 |
| deserpidinum [inn-latin] |
| einecs 205-004-8 |
| desmethoxyreserpine |
| methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat |
| brn 0101820 |
| nsc 72138 |
| deserpidine [inn:ban] |
| 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) |
| reserpidine |
| methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate |
| lilly 22641 |
| tranquinil |
| methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester) |
| deserpidina [inn-spanish] |
| desepridine |
| nsc-72138 |
| benz[g]indolo[2, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate |
| canescin |
| recanescin |
| 17.alpha.-methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester |
| harmonyl |
| raunormine |
| deserpidin |
| raunormin |
| yohimban-16-carboxylic acid, 17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3b,16b,17a,18b,20a)- |
| NSC72138 , |
| deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate |
| 131-01-1 |
| deserpidine |
| C06541 |
| (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester |
| CHEBI:27478 , |
| recanescine |
| methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate |
| 11-desmethoxyreserpine |
| 11-demethoxyreserpine |
| canescine |
| DB01089 |
| NCGC00168786-02 |
| NCGC00168786-01 |
| deserpidine, (-)- |
| CHEMBL1200515 |
| halmonyl |
| halmonyl (tn) |
| deserpidine (inn) |
| D08194 |
| unii-9016e3vb47 |
| deserpidina |
| deserpidinum |
| 4-25-00-01282 (beilstein handbook reference) |
| 9016e3vb47 , |
| dtxsid8020383 , |
| tox21_112646 |
| cas-131-01-1 |
| tox21_113102 |
| dtxcid80383 |
| deresperine |
| deserpidine [inn] |
| deserpidine [vandf] |
| enduronyl component deserpidine |
| deserpidine [who-dd] |
| oreticyl forte component deserpidine |
| deserpidine component of enduronyl |
| deserpidine [orange book] |
| methyl 17.alpha.-methoxy-18.beta.-((3,4,5-trimethoxybenzoyl)oxy)-3.beta.,20.alpha.-yohimban-16.beta.-carboxylate |
| deserpidine [mi] |
| deserpidine component of oreticyl forte |
| deserpidine [mart.] |
| AKOS015896464 |
| gtpl7064 |
| methyl (1r,15s,17r,18r,19s,20s)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
| SCHEMBL259343 |
| smr004701248 |
| MLS006010113 |
| MD-0232 , |
| (1s,2r,3r,4as,13br,14as)-methyl 2-methoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate |
| methyl (1r,15s,17r,18r,19s,20s)-18-methoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate |
| bdbm50480272 |
| J-005923 |
| Q5263885 |
| HY-107339 |
| CS-0028177 |
| yohimban-16-carboxylic acid,17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester,(3b,16b,17a,18b,20a)- |
| F82150 |
| methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylate |
| deserpidinum (inn-latin) |
| deserpidine (mart.) |
| (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylic acid methyl ester |
| deserpidina (inn-spanish) |
| c02aa05 |
| methyl (1r,15s,17r,18r,19s,20s)-18-methoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate |
| EN300-19736832 |
Deserpidine (2) is a compound with limited availability from natural sources. Its synthesis from 1 in six steps (41% overall yield) is reported here.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deserpidine (2) is a compound with limited availability from natural sources, and its synthesis from 1 in six steps (41% overall yield) is reported here." | ( Synthesis of deserpidine from reserpine. Baldelli, E; Battaglia, A; Bombardelli, E; Danieli, B; Fontana, G; Guerrini, A; Samorì, C; Varchi, G, 2005) | 1.42 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| yohimban alkaloid | |
| alkaloid ester | |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| benzoate ester | Esters of benzoic acid or substituted benzoic acids. |
| organic heteropentacyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 4.5131 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 9.3851 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.9554 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 9.0984 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.1220 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 12.9835 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 17.9025 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 0.3548 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 8.7376 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 7.0795 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 3.3498 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 2.4428 | 0.0056 | 12.3677 | 36.1254 | AID624032; AID624044 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 7.0795 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 16.4224 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID397122 | Inhibition of HIV1 RT | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 38 (84.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.44) | 29.6817 |
| 2010's | 2 (4.44) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 48 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||